ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

10964	Companies
240038	Keywords
168782	Articles
129138	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

BRIEF

published on 09/26/2025 at 07:05, 11 months 15 days ago

Strategic Partnership for Innovation in Immunotherapy

Strategic Partnership Oncology Industrial Support Immunotherapy Innovation Collaborative Research
PRESS RELEASE

published on 09/26/2025 at 07:00, 11 months 15 days ago

OSE Immunotherapeutics, Inserm Transfert et Nantes Université annoncent un partenariat stratégique pour accélérer l’innovation en immunothérapie
Partenariat stratégique entre OSE Immunotherapeutics, Inserm Transfert et Nantes Université pour accélérer l'innovation en immunothérapie. Objectif : transformer découvertes académiques en thérapies de rupture

Partenariat Immunothérapie OSE Immunotherapeutics Inserm Transfert Nantes Université
PRESS RELEASE

published on 09/26/2025 at 07:00, 11 months 15 days ago

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
OSE Immunotherapeutics, Inserm Transfert, and Nantes University form a strategic partnership to advance immunotherapy for oncology, inflammation, and autoimmunity. The collaboration combines academic research and industrial expertise

Innovation Partnership Oncology Collaboration Immunotherapy
BRIEF

published on 09/24/2025 at 08:05, 11 months 17 days ago

OSE Immunotherapeutics Corrects Voting Rights Error Before General Meeting

Voting Rights Shareholder Meeting Accusations Material Error Proxy Firms
BRIEF

published on 09/24/2025 at 08:05, 11 months 17 days ago

OSE Immunotherapeutics corrige une erreur de droit de vote avant l'assemblée générale

Droit De Vote Assemblée Des Actionnaires Erreur Matérielle Accusations Sociétés De Procuration
PRESS RELEASE

published on 09/24/2025 at 08:00, 11 months 17 days ago

Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
OSE Immunotherapeutics corrects material error in total number of shares and voting rights, refutes accusations, and provides clarity on shareholder agreements and proxy advisory recommendations

Correction Proxy Advisory Shareholder Agreements OSE Immunotherapeutics Material Error
BRIEF

published on 09/23/2025 at 22:35, 11 months 17 days ago

OSE Immunotherapeutics Responds to Court Decision

General Meeting Shareholder Rights OSE Immunotherapeutics Nantes Commercial Court Voting Rights Error
BRIEF

published on 09/23/2025 at 22:35, 11 months 17 days ago

OSE Immunotherapeutics répond à la décision du tribunal

Assemblée Générale Droits Des Actionnaires OSE Immunotherapeutics Tribunal De Commerce De Nantes Erreur Relative Aux Droits De Vote
PRESS RELEASE

published on 09/23/2025 at 22:30, 11 months 17 days ago

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court regarding a shareholder action and prepares for the General Meeting on September 30, 2025, ensuring transparency and commitment

Transparency General Meeting OSE Immunotherapeutics Shareholder Action Nantes Commercial Court
PRESS RELEASE

published on 09/23/2025 at 22:30, 11 months 17 days ago

OSE Immunotherapeutics prend acte de la décision du Tribunal de commerce de Nantes
OSE Immunotherapeutics prend acte de la décision du Tribunal de commerce de Nantes rejetant ses demandes. Erreur matérielle identifiée dans le calcul des droits de vote. Préparation de l'Assemblée Générale le 30 septembre 2025

Biotechnologie Assemblée Générale Tribunal De Commerce OSE Immunotherapeutics Décision

Accesswire

Published on 09/11/2026 at 04:00, 7 hours 51 minutes ago

Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 13 hours 26 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 18 hours 5 minutes ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 20 hours 31 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 20 hours 51 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 11:45, 5 minutes ago

Halfords Group PLC: Result of AGM
Published on 09/11/2026 at 11:43, 8 minutes ago

Skyborn reaches Financial Close on the Gennaker offshore wind farm project
Published on 09/11/2026 at 11:35, 15 minutes ago

EQS-Adhoc: Correction of a release from 10/09/2026, 19:35 CET/CEST - United Internet AG: Group subsidiaries 1&1 AG and IONOS Group SE launch transformation programs
Published on 09/11/2026 at 11:30, 21 minutes ago

Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Published on 09/11/2026 at 10:15, 1 hour 36 minutes ago

TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050

Les Echos

Published on 09/11/2026 at 07:00, 4 hours 51 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 4 hours 51 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 4 hours 51 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 4 hours 51 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 16 hours 21 minutes ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE